ДИБАС Мохаммед И. (US),ЧОУ Кен (US),ДОНЕЛЛО Джон Е. (US),ГАРСТ Майкл Е. (US),ДЖИЛ Дэниел В. (US),ВАНГ Лиминг (US)
申请号：
RU2013116405/15
公开号：
RU2013116405A
申请日:
2011.09.16
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method of treating skin diseases and skin conditions in a subject in need of such treatment, comprising administering a therapeutically effective amount of a composition containing a compound of Formula I, its individual enantiomers, its individual diastereoisomers, its hydrates, its solvates, its crystalline forms, its individual isomers , individual tautomers thereof or a pharmaceutically acceptable salt thereof, wherein R is H or C1-6alkyl； R is H or C1-6alkyl； R is H, C1-6alkyl, heterocycle or aryl； and R is C1-6alkyl, heterocycle or aryl. 2. The method according to claim 1, characterized in that the compound is a compound of Formula II, its individual diastereoisomers, its hydrates, its solvates, its crystalline forms, its individual isomers, its individual tautomers or its pharmaceutically acceptable salt, where R is H or C1-6alkyl； R is H or C 1-6 alkyl； R is H, C 1-6 alkyl, heterocycle or aryl； and R is C1-6alkyl, heterocycle or aryl. 3. The method according to claim 1, characterized in that the compound is a compound of Formula III, its individual diastereoisomers, its hydrates, its solvates, its crystalline forms, its individual isomers, its individual tautomers or its pharmaceutically acceptable salt, where R is H or C1-6alkyl； R is H or C 1-6 alkyl； R is H, C 1-6 alkyl, heterocycle or aryl； and R is C1-6alkyl, heterocycle or aryl. 4. The method according to claim 2, characterized in that R is C1-6alkyl, R is C1-6alkyl, R is H, and R is C1-6alkyl. The method according to claim 2, characterized in that R is methyl, R is methyl, R is H, and R is C1-6alkyl. The method according to claim 2, characterized in that the compound is selected from: iso-butyric acid 3 - [(S) -1- (1H-imidazol-4-yl) ethyl] -2-methyl-benzyl ether； 2.2 dimethyl propiones1. Способ лечения заболеваний кожи и состояний кожи у субъекта, нуждающегося в таком лечении, включающий введение терапевтически эффективного количества композиции, содержащей соединение Формулы I, его отдельные эна
